Other Trials Clinical Trials

Showing 1-3 of 3 items
1.
  • Bortezomib Plus Rituximab for Initial Therapy of EBV+ PTLD
  • Post transplant lymphoproliferative disease (PTLD) is a type of B-cell non-Hodgkin lymphoma that occurs in patients with weakened immune systems due to immunosuppressive medications taken after organ or stem cell transplantation. This is usually related to a virus called Epstein-Barr (EPV). Rituximab is a type of drug called an "antibody" that specifically destroys both normal and cancerous B-cells, and is commonly used for PTLD. Bortezomib is a drug that has been approved by the Food and Drug Administration (FDA) to treat multiple myeloma and a B-cell non-Hodgkin lymphoma called Mantle Cell Lymphoma, and shows significant activity in lymphoma cells caused by EBV. In this research study, we hope to learn if the addition of bortezomib to rituximab treatment can increase the rate of complete remissions and cures of PTLD after organ or stem cell transplant.
  • Diagnoses: Other Trials
  • Status: Recruiting
2.
3.
Showing 1-3 of 3 items
  • Email
  • Print
  • Share
  • Text
Highlight Glossary Terms